Intech Investment Management LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Intech Investment Management increased its Alnylam Pharmaceuticals stake by 703.7% in the fourth quarter, bringing its holdings to 46,710 shares valued at about $18.6 million.
• Alnylam reported strong quarterly results, posting $1.99 EPS versus the $0.87 estimate and revenue of $1.17 billion, which was up 96.4% year over year.
• Wall Street remains broadly positive on the stock, with a consensus Moderate Buy rating and an average target price of $463.13, though some recent analyst targets were trimmed.

Intech Investment Management LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 703.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,710 shares of the biopharmaceutical company's stock after purchasing an additional 40,898 shares during the period. Intech Investment Management LLC's holdings in Alnylam Pharmaceuticals were worth $18,574,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company's stock worth $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Capital Research Global Investors boosted its position in Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company's stock valued at $3,293,516,000 after buying an additional 31,184 shares during the last quarter. Groupama Asset Managment grew its stake in shares of Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company's stock valued at $18,610,000 after acquiring an additional 2,483,697 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company's stock worth $1,056,884,000 after acquiring an additional 151,480 shares during the last quarter. Finally, Orbis Allan Gray Ltd increased its position in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after acquiring an additional 486,489 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 3.2%

NASDAQ:ALNY opened at $305.06 on Friday. The company has a market cap of $40.73 billion, a PE ratio of 83.35 and a beta of 0.31. The business's 50 day moving average is $309.63 and its two-hundred day moving average is $355.11. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52 week low of $284.28 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts' consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned ($0.44) EPS. The business's quarterly revenue was up 96.4% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating for the company in a research note on Friday, January 30th. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an "equal weight" rating in a research report on Friday, May 1st. Freedom Capital upgraded Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 17th. Needham & Company LLC decreased their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating for the company in a research report on Thursday, February 12th. Finally, Chardan Capital restated a "buy" rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $463.13.

Insider Activity

In related news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares in the company, valued at $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Pushkal Garg sold 1,775 shares of the firm's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the completion of the transaction, the executive vice president directly owned 23,406 shares in the company, valued at $7,483,834.44. This represents a 7.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 21,255 shares of company stock valued at $6,930,337 over the last quarter. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.